The current experiment was conducted to evaluate whether prolongation of infusion time is useful for the amelioration of nedaplatin (NDP)-induced nephrotoxicity. Eight-week-old male rats were treated with 12 mg/kg NDP with the following dosing protocols, bolus injection, 1-or 4-hour continuous infusions (1hIF or 4hIF, respectively), and sacrificed 3 days after dosing. Urinary parameters were monitored on the day of the sacrifice, and the kidneys and femurs were removed for histopathological examination and bone marrow analysis. In the Bolus-NDP group, urine pH and specific gravity were decreased compared with the corresponding control group and glucosuria and occult blood were detected, while no abnormalities were noted in these urine parameters in the 4hIF-NDP group. Histopathological examination revealed slight to moderate renal lesions, such as single cell and/or focal necrosis in the epithelium of cortical tubules and collecting ducts in the renal papilla in the Bolus-NDP group. In the 1hIF-and 4hIF-NDP groups, there were clear reductions in the severity of renal tubular damage compared with the Bolus-NDP group, and the severity of renal tubular damage tended to reduce with increased infusion time. A TUNEL assay revealed that the numbers of TUNEL-positive cells in the 1hIF-and 4hIF-NDP groups were significantly lower than that in the Bolus-NDP group. There was a significant decrease in the number of TUNEL-positive cells in the 4hIF-NDP group compared with that in the 1hIF-NDP group. However, prolongation of the infusion time had no clear effect on the myelotoxicity of NDP. These results provide new evidence that prolongation of the infusion time is effective at minimizing the nephrotoxicity of NDP. (J Toxicol Pathol 2007; 20: 141-147) 
Introduction
Nedaplatin [cis-diammineglycolatoplatinum (II), NDP] is a second-generation antineoplastic platinum complex with reduced nephrotoxicity. It is now marketed in Japan as a drug, which may serve as a substitute for cisplatin [cisdiamminedichloroplatinum (II), CDDP] or even surpass it for use in combination with other drugs 1 -6 . While nephrotoxicity occurs less frequently, the NDP dose is limited by the fact that it can cause myelosuppression, resulting in thrombocytopenia 7 . Previously, we have reported that while NDP is clearly less nephrotoxic than CDDP in rats, it also induces nephrotoxicity, which is morphologically characterized by lysosomal hyperplasia, necrosis and hyperplasia of the collecting duct epithelium and epithelium covering the renal papilla, with slight cortical lesions, such as proximal tubular dilatation and regeneration 8 . Therefore, attention must be paid to the nephrotoxicity of NDP during use, especially in patients with reduced renal function, even though it is a promising drug with reduced nephrotoxicity. The toxicological information currently available is limited and additional experimental studies focused on the amelioration of NDP's nephrotoxicity are necessary. Thus, in the current study, we evaluated whether prolongation of infusion time would be useful for ameliorating the nephrotoxicity of NDP at a therapeutic dose level.
Materials and Methods

Chemicals
Nedaplatin [cis-diammineglycolatoplatinum (II), NDP] was obtained from our laboratory (Shionogi & Co., Ltd., Osaka, Japan).
Animals and housing conditions
All experimental procedures were conducted after All experiments were performed on 8-week-old male Wistar rats (Japan SLC Inc., Shizuoka, Japan). The animals were housed in plastic cages in an environment-controlled room kept at 23 ± 1°C, 45-65% humidity, with a 12-hour lighting period (light on: 8:00-20:00). All animals were allowed free access to food (autoclaved rat chow CA-1, Clea Japan Inc., Tokyo, Japan) and water (sterilized city water via an automatic water supplying system).
Experimental design
The day of administration was designated as Day 0. NDP was dissolved in 5% xylitol solution before use. NDP was injected intravenously in a single dose of 12 mg/kg with the following infusion times: a bolus injection (Bolus-NDP group, n = 6), 1-hour or 4-hour continuous infusions (1hIF-or 4hIF-NDP groups, n = 6 or 5, respectively). Control rats received the vehicle alone under the corresponding infusion conditions (Bolus-, 1hIF-or 4hIF-Cont groups, n = 4, respectively). For the bolus injection, NDP (2 mL/kg, at a concentration of 6 mg/mL) was injected rapidly via the tail vein. For the continuous infusion, the NDP solution (6 mg/ mL) was further diluted with the vehicle at a concentration of 0.6 mg/mL, which was infused through an indwelling needle placed in the caudal vein at a constant flow rate of 20 or 5 mL/kg/h for 1 or 4 hours, respectively. Body weight, residual amounts of food (Days 0 to 3) or water supplied (Day 3 only) on the previous day were measured daily in the morning. After the collection of a urine sample on the day of the sacrifice (Day 3), each animal was euthanized by exsanguination after cutting both the abdominal aorta and vena cava under deep anesthesia with pentobarbital sodium, and the kidneys and femurs (including bone marrow) were removed.
Urinalysis
Each animal was maintained in individual metabolic cages on Day 3, and consecutive 4-hour urine samples were collected under fasting and no-watering conditions. After urine volume was measured and color was observed, specific gravity (digital refractometer UR-S, Atago, Tokyo, Japan) was measured. The pH, protein, glucose, ketone bodies, urobilinogen, bilirubin, and occult blood were determined using Multistix and an automatic analyzer Clinitek 200+ (Bayer Medical Ltd., Tokyo, Japan).
Bone marrow analysis
The number of nucleated bone marrow cells (NBMC) in the right femur was determined according to the following methods modified from a previous report 9 . Briefly, after the femur was removed and freed of soft tissue attachments, the epiphyseal cap was detached from the proximal end and the extreme distal tip of each epicondyle was cut off. A suspension of the bone marrow was prepared by injecting 1.5% acetic acid solution into the femurs to lyse erythrocytes and flush out cells. Nucleated cells in the suspension were counted using an automatic blood cell analyzer (T540, Beckman Coulter, Inc., Fullerton, CA, USA), and the number of NBMC per the bone marrow weight of a femur (×10 6 /mg) was then calculated.
Histopathological examination
For light microscopic examination, kidney samples were fixed in 10% neutral buffered formalin, dehydrated in alcohol and embedded in paraffin. The left femur samples were decalcified in a mixture of 10% formic acid and formalin, before the specimens were prepared. Paraffin sections were prepared and stained by a routine method with hematoxylin and eosin (H&E). The histopathological changes were graded by a pathologist in a blind and random manner according to the following criteria: (a) renal tubular lesions: ±, very slight, 1-10% tubules affected within the kidney section; +, slight, 10-25%; 2+, moderate, 25-50%; 3 + , s e v e r e , o v e r 5 0 % t u b u le s ; ( b) b on e m a r r o w hypocellularity: ±, very slight; +, slight; 2+, moderate; 3+, severe. All specimens were further reviewed by another pathologist for confirmation of the results.
TUNEL assay for apoptosis
A TUNEL assay was performed on kidney sections from the NDP-treated groups using an ApopTag ® Peroxidase In Situ Apoptosis Detection Kit (Chemicon International, Inc., Temecula, CA, USA) according to manufacturer's protocols. Briefly, the kidney sections were deparaffinized and rehydrated, followed by incubation with proteinase K (Dako Corporation, Carpinteria, CA, USA) for 15 min at room temperature, and immersion in PBS (pH 7.4) containing 3% H 2 O 2 to inactivate endogenous peroxidase. Equilibration buffer was applied to the sections for 30 min at room temperature, followed by reaction with TdT enzyme and reaction buffer at 37°C for 60 min. Avidin-horseradish peroxidase solution was applied to the sections, and the staining was visualized with diaminobenzidine. Sections were then counter-stained with Mayer's hematoxylin, dehydrated, and mounted. A semiquantitative analysis was performed by counting the number of TUNEL-positive cells per field at ×400 magnification in both the renal cortex and papilla. The mean numbers of stained cells in 20 fields in each renal zone of the kidney section were expressed as the number of TUNEL-positive cells.
Statistical analysis
All numerical data were expressed as mean ± standard error (S.E.). Data on body weight, food consumption, water consumption, urinalysis (urine volume, specific gravity, pH), NBMC, and the TUNEL assay were analyzed by Tukey's multiple comparison test. Results were considered significant when the p value was less than 0.05.
Results
Mortality, body weight and food consumption
One of the 6 animals in the Bolus-NDP group died on day 3. No deaths were observed in the other groups. In all the NDP-treated groups, there was a significant decrease in body weight (Fig. 1A) associated with a decrease in food consumption (Fig. 1B) throughout the study period, which was partially reduced by continuous infusion.
Urinary parameters
In all the NDP-treated groups, there was a tendency for urine volume to decrease with or without statistical significance compared with the corresponding control group (Fig. 2B ) which was associated with a decrease in water consumption ( Fig. 2A) . In the Bolus-and 1hIF-NDP groups, urine specific gravity showed a tendency to decrease without statistical significance compared with the corresponding control group, while no abnormality was observed in the 4hIF-NDP group (Fig. 2C) . In the Bolus-NDP group, low urine pH (5.0 to 5.5), glucosuria (2+ to 4+, 250 to 1,000 mg/ dL) and occult blood (1+ to 2+) were detected, while abnormalities in these parameters were observed in neither the 1hIF-nor the 4hIF-NDP groups (normal range of data: 6.0 to 7.0 for pH, negative for glucose and occult blood). No abnormalities attributable to NDP-treatment were observed in the other urinary parameters.
Bone marrow analysis
There was no significant difference between the 1hIF-and 4hIF-NDP groups in the number of NBMC, while the numbers in both the 1hIF-and 4hIF-NDP groups were significantly higher than that in the Bolus-NDP group (Table  1) . 
Histopathological examination
As shown in Table 2 , all rats in the Bolus-NDP group displayed slight to moderate renal tubular lesions, such as focal necrosis and degenerative appearances manifesting loss of brush borders and intracytoplasmic abnormally large vacuoles, and single cell necrosis, characterized by shrunken cytoplasm with pyknotic and fragmented nuclei in the tubular epithelium of the renal cortex and corticomedullary zone (Fig. 3A) . In addition, morphological abnormalities caused by NDP were not restricted to the renal cortex, and single cell necrosis and hyaline droplets were observed in the collecting duct epithelium and the epithelium covering the renal papilla (Fig. 3B) .
In comparison with the Bolus-NDP group, there was a clear reduction in the incidence and the severity of renal lesions in the 1hIF-and 4hIF-NDP groups (Fig. 3C and D) . In particular, focal necrosis of the cortical renal tubules was not observed in both the 1hIF-and 4hIF-NDP groups. The incidence and the severity of renal lesions in the 1hIF-and 4hIF-NDP groups, such as single cell necrosis and tubular degeneration, were substantially reduced in comparison with the Bolus-NDP group. In the 4hIF-NDP group, only a few animals showed single cell necrosis graded as very slight in the renal cortex.
In contrast, all of the NDP-treated rats showed slight to moderate hypocellularity in the bone marrow. In comparison with the Bolus-NDP group, the incidence of the bone marrow lesion showed a tendency to reduce in 1hIF-and 4hIF-NDP groups. However, there was no clear reduction in the severity of the lesions in the 4hIF-NDP group compared with that in the 1hIF-NDP group.
TUNEL assay for apoptosis
As shown in Fig. 4 , the numbers of the TUNELpositive cells in the 1hIF-and 4hIF-NDP groups were significantly lower than that in the Bolus-NDP group in both the renal cortex and papilla. In the 4hIF-NDP group, the number of TUNEL-positive cells showed a tendency to decrease with or without statistical significance compared with that in the 1hIF-NDP group in both the renal cortex and papilla.
Discussion
Several platinum complexes possessing antitumor properties have been synthesized. Cisplatin [cisdiamminedichloroplatinum (II), CDDP] is one of the most potent agents used in chemotherapy for various types of cancer. However, despite its effectiveness as an antitumor d r u g , i t s c l i n i c a l u s e i s r e s t r i c t e d b y i t s s e v e r e Rats were sacrificed 3 days after drug administration. All data are expressed as mean ± S.E. (n = 4 to 6). **: Significant difference from corresponding control groups, p < 0.01.
##
: Significant difference from bolus nedaplatin-treated group, p < 0.01. nephrotoxicity, which can lead to acute renal failure [10] [11] [12] . To resolve the problem of this dose-limiting nephrotoxicity, several investigators have attempted to alter the schedule of administration or find ways to ameliorate it in experimental animals with the ultimate aim of application to humans. These efforts have led to optimal dosing protocols designed to minimize the nephrotoxicity, including longer continuous infusions 13, 14 and the use of hydration and osmotic diuresis [15] [16] [17] . Nevertheless, approximately one-third of patients receiving CDDP still develop evidence of acute renal failure 16, 18, 19 . A wealth of toxicological data is available concerning CDDP-induced nephrotoxicity. Relevant perhaps to the nephrotoxicity of CDDP are the observations that the kidney retains platinum to a greater extent than other organs and is the predominant excretory organ for CDDP [22] [23] [24] . Several experimental studies have confirmed that CDDP primarily affects the lower straight part (S3 segment) of the proximal tubules, the principal site of platinum accumulation, in the corticomedullary zone in rats 25, 26 . This preferential accumulation of platinum seems to be a major cause of the nephrotoxicity of CDDP.
NDP is a promising antineoplastic platinum complex with reduced nephrotoxicity. Kawai et al. 27 showed that renal accumulation of platinum when cisplatin was administered at 3.75 mg/kg was similar to that of NDP administered at 24 mg/kg, and that both drugs at these two doses induced similar effects in the kidney. It was inferred, therefore, that the nephrotoxicity of NDP was lower than that of CDDP due to lower accumulation of platinum. Sugeno et al. 28 reported that the plasma levels of platinum decreased in a bi-exponential manner in male rats after a single intravenous bolus dose of 3 mg/kg NDP; the half-lives of the α-and β-phase were 1.7 and 14.5 minutes and most of the plasma platinum was of the free form. They also demonstrated that approximately over 85% of the total dose of platinum was excreted in urine within 6 hours after a single intravenous dose. Therefore, NDP is rapidly excreted from blood into urine after dosing.
In the current study, a single bolus intravenous dose of 12 mg/kg NDP was administered, which corresponds to an approximate 62 mg/m 2 body surface area based on a method previously published 20 . However, there were several morphological abnormalities in the kidney treated with NDP as a single bolus dose. This result suggests that NDP also has the potential to cause nephrotoxicity at a dose within the therapeutic range for clinical use (50-100 mg/m 2 ) 21 . In the present study, we also evaluated whether continuous infusion could ameliorate NDP-induced nephrotoxicity. We found that morphological abnormalities in kidneys treated with NDP by 4-hour infusion were milder than those given NDP by bolus or 1-hour infusion, in spite of the same dose being given. This finding indicates that the nephrotoxicity of NDP can be reduced by prolongation of its infusion time. On the other hand, prolongation of the infusion time of NDP dosing had no clear effects on the myelotoxicity. Although pharmaco/toxicokinetic data were not available under the current experimental conditions, we consider that nephrotoxicity attributable to NDP was probably avoided by prevention of temporary elevation of urine platinum concentration because of the prolonged infusion time.
In summary, our present results provide new evidence that prolongation of infusion time is effective at minimizing the nephrotoxicity of NDP. Our findings offer valuable information for the consideration of the clinical therapeutic use of NDP.
